Oncology Research Editorial Office

Oncology Research, Vol.32, No.11, pp. 1813-1813, 2024, DOI:10.32604/or.2024.056888 - 16 October 2024

Abstract This article has no abstract. More >

Ning Wang^*1, Tingting Zhang^†1

Oncology Research, Vol.26, No.7, pp. 1005-1014, 2018, DOI:10.3727/096504017X15144755633680

Abstract Personalized treatment targeting the epidermal growth factor receptor (EGFR) may be a promising new treatment of non-small cell lung cancer (NSCLC). Gefitinib, a tyrosine kinase inhibitor, is the first drug for NSCLC, which unfortunately easily leads to drug resistance. Our study aimed to explore the functional role of microRNA (miR)-135 in the sensitivity to gefitinib of NSCLC cells. Expression of miR-135 in normal cells and NSCLC cells was assessed, followed by the effects of abnormally expressed miR-135 on cell viability, migration, invasion, apoptosis, sensitivity to gefitinib, and the expression levels of adhesion molecules and programmed… More >

Hongwei Tan, Jin Qi, Guanghua Chu, Zhaoyang Liu

Oncology Research, Vol.25, No.4, pp. 551-558, 2017, DOI:10.3727/096504016X14758370595285

Abstract Tripartite motif 16 (TRIM16), a member of the RING B-box coiled-coil (RBCC)/tripartite motif (TRIM) protein family, has been shown to play a role in tumor development and progression. However, the role of TRIM16 in ovarian cancer has never been revealed. Thus, in this study, we investigated the roles and mechanisms of TRIM16 in ovarian cancer. Our results demonstrated that TRIM16 expression was low in ovarian cancer cell lines. In addition, overexpression of TRIM16 significantly inhibited the migration and invasion in vitro, as well as suppressed the epithelial–mesenchymal transition (EMT) phenotype in ovarian cancer cells. Furthermore, More >